Physical activity, high-sensitivity C-reactive protein, and total and cardiovascular disease mortality in type 2 diabetes

Diabetes Care

Volumn 34, Issue 7, 2011, Pages 1492-1496

  Vepsäläinen, Teemu ^a   Soinio, Minna ^a   Marniemi, Jukka ^b   Lehto, Seppo ^c   Juutilainen, Auni ^c   Laakso, Markku ^c   Rönnemaa, Tapani ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL ACTIVITY; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; FINLAND; MIDDLE AGED; MOTOR ACTIVITY; PROPORTIONAL HAZARDS MODEL;

C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; FINLAND; HUMANS; MALE; MIDDLE AGED; MOTOR ACTIVITY; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES;

EID: 80054689601     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-0469     Document Type: Article

References (25)

1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115-126
2. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-979 (Pubitemid 27152782)
3. Soinio M, Marniemi J, Laakso M, Lehto S, Rönnemaa T. High-sensitivity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes: a 7-year follow-up study. Diabetes Care 2006;29:329-333 (Pubitemid 44106513)
4. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-234 (Pubitemid 28350165)
5. Balducci S, Zanuso S, Nicolucci A, et al. Anti-inflammatory effect of exercise training in subjects with type 2 diabetes and the metabolic syndrome is dependent on exercise modalities and independent of weight loss. Nutr Metab Cardiovasc Dis 2010;20:608-617
6. Aronson D, Sheikh-Ahmad M, Avizohar O, et al. C-Reactive protein is inversely related to physical fitness in middle-aged subjects. Atherosclerosis 2004;176:173-179 (Pubitemid 39078660)
7. Laakso M, Rönnemaa T, Pyörälä K, Kallio V, Puukka P, Penttilä I. Atherosclerotic vascular disease and its risk factors in noninsulin-dependent diabetic and nondiabetic subjects in Finland. Diabetes Care 1988;11: 449-463
8. Rose G, Blackburn H, Gillum RF, Prineas RJ. Cardiovascular Survey Methods. 2nd ed. Geneva, World Health Org., 1982
9. World Health Organization. Proposal for the Multinational Monitoring of Trends and Determinants in Cardiovascular Disease and Protocol (MONICA Project). Geneva, World Health Org., 1983(WHO/MNC/82.1, Rev. 1)
10. Walker AE, Robins M, Weinfeld FD. The national survey of stroke: clinical findings. Stroke 1981;12(Suppl. 1):I13-I44
11. van Kley H, Hale SM. Assay for protein by dye binding. Anal Biochem 1977;81:485-487 (Pubitemid 8175064)
12. Mälkiä E, Impivaara O, Maatela J, Aromaa A, Heliövaara M, Knekt P. Physical Activity of Finnish Adults. Turku, Finland, Publications of the Social Insurance Institution, 1988 (series ML:80)
13. Vepsäläinen T, Soinio M, Lehto S, Juutilainen A, Laakso M, Rönnemaa T. Proteinuriamodifies the effects of physical activity on total and cardiovascular disease mortality rates in patients with type 2 diabetes. Diabetologia 2010;53:1886-1889
14. Pearson TA, Mensah GA, Alexander RW, et al.; Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511 (Pubitemid 36158056)
15. Lagrand WK, Visser CA, Hermens WT, et al. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation 1999;100:96-102 (Pubitemid 29297946)
16. Calabro P, Chang DW, Willerson JT, Yeh ET. Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation. J Am Coll Cardiol 2005;46: 1112-1113 (Pubitemid 41316523)
17. Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 2001; 158:1039-1051 (Pubitemid 32221796)
18. Labarrere CA, Zaloga GP. C-reactive protein: from innocent bystander to pivotal mediator of atherosclerosis. Am J Med 2004;117:499-507 (Pubitemid 39349588)
19. Festa A, D'Agostino R Jr, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102:42-47 (Pubitemid 30430551)
20. Weight LM, Alexander D, Jacobs P. Strenuous exercise: analogous to the acute-phase response? Clin Sci (Lond) 1991;81: 677-683
21. Ostrowski K, Rohde T, Asp S, Schjerling P, Pedersen BK. Pro- and anti-inflammatory cytokine balance in strenuous exercise in humans. J Physiol 1999;515:287-291 (Pubitemid 29092641)
22. Ostrowski K, Rohde T, Zacho M, Asp S, Pedersen BK. Evidence that interleukin-6 is produced in human skeletal muscle during prolonged running. J Physiol 1998; 508:949-953 (Pubitemid 28220743)
23. Kasapis C, Thompson PD. The effects of physical activity on serum C-reactive protein and inflammatory markers: a systematic review. J Am Coll Cardiol 2005; 45:1563-1569 (Pubitemid 40704486)
24. Lakka TA, Lakka HM, Rankinen T, et al. Effect of exercise training on plasma levels of C-reactive protein in healthy adults: the HERITAGE Family Study. Eur Heart J 2005;26:2018-2025 (Pubitemid 41435729)
25. Ridker PM, Rifai N, Clearfield M, et al.; Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-1965 (Pubitemid 32568149)